Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (23252)	3/21/2007 8:33:30 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

RBC seems to have a better impression of Dimebon than you... 09:42 am Medivation: RBC Capital Mkts initiates Outperform. Target $24. RBC initiates MDVN with an Outperform and $24 tgt. Firm says their positive MDVN thesis is based on what they believe is some of the most impressive placebo-controlled Phase II data in Alzheimer's disease and if replicated in a planned US Phase II trial, could lead to a major partnership, multi-billion dollar revenue opportunity, and significant upside to the stock. Even with only modest efficacy, they believe Dimebon could be a billion-dollar drug.